clinical practice guidelines

Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Approved by the ESMO Guidelines Working Group: December 2006 last update March 2010. This publication supercedes the previously published version—Ann Oncol 2009; 20 (Suppl 4): iv64-iv67.

Conflict of interest: Dr Casali has reported that he is currently conducting research sponsored by Novartis and Pfizer, he had a consultancy role with and/or received honoraria for lectures from Novartis and Pfizer, he has received travel coverage for medical meetings from Novartis; Prof. Blay has reported that he is a consultant for Pfizer, Novartis, GSK, Roche and Pharmamar.

Consensus panel's conflict of interest: Prof. Aglietta has reported that he has received research grants from Bayer, Amgen, Roche and Novartis; Prof. Alvegård has reported no conflicts of interest; Dr Athanasou has reported no conflicts of interest; Dr Bihn has not reported any conflicts of interest; Dr Bonvalot has reported that she has received honoraria from Novartis and grants from Pharmamar; Dr Boukovinas has reported that he is a member of the speakers' bureau for Novartis; Prof. De Alava has reported no conflicts of interest; Dr Dei Tos has reported no conflicts of interest; Dr Dileo has r reported no conflicts of interest; Dr Eriksson has reported that he has received honoraria from Novartis, MSD, Pfizer, Swedish Orphan and GSK; Dr A. Ferrari has reported no conflicts of interest; Dr S. Ferrari has reported no conflicts of interest; Dr Garcia Del Muro has reported no conflicts of interest; Dr Gronchi has reported that he has received honoraria and compensations as member of the advisory board and research funds from Novartis; Dr Hall has reported no conflicts of interest; Prof. Hassan has reported that at present he has no conflicts of interest, but he is planning trials with Takeda and Pharmamar; Prof. Hogendoorn has reported no conflicts of interest; Dr Hohenberger has not reported any conflicts of interest; Dr Gelderblom has reported no conflicts of interest; Dr Grimer has reported no conflicts of interest; Prof. Issels has reported no conflicts of interest; Dr Joensuu has reported no conflicts of interest; Dr Jost has reported no conflicts of interest; Prof. Judson has reported that he has received honoraria for attendance at advisory board meetings and speaking engagement from Novartis and Pfizer; Dr Juergens has reported no conflicts of interest; Dr Le Cesne has reported that he has received honoraria from Novartis, Pfizer and PharmaMar; Dr Leyvraz has not reported any conflicts of interest; Dr Martin-Broto has reported no conflicts of interest; Dr Montemurro has reported no conflicts of interest; Prof. Nishida has reported that he is currently conducting research partly funded by Novartis Pharma; Dr Shreyaskumar has reported that he is on the speakers' bureau and receive honoraria from Novartis; Dr Reichardt has reported that he is a member of the speakers' bureau for Novartis and Pfizer and a member of the Advisory Board for Novartis, Pfizer and Bayer, he is also conducting research sponsored by Novartis; Dr Robinson has reported no conflicts of interest; Dr Rutkowski has reported that he has received honoraria from Novartis and Pfizer and that he is a member of the speakers' bureau and of the advisory board for Novartis; Prof. Schöffski has reported that he is conducting research sponsored by Novartis, Pfizer, PharmaMar, Eisai, GlaxoSmithKline, Infinity and Genentech and that he is a member of the speakers' bureau for Novartis, Pfizer, PharmaMar, Eisai, GlaxoSmithKline; Dr Schlemmer has reported that he is currently conducting research funded by Novartis and Pfizer; Dr Sleijfer has reported that he has received research funding from Novartis and Pfizer; Dr Van der Graaf has reported no conflicts of interest; Dr Vanel has reported no conflicts of interest; Prof. Verweij has reported that he has received honoraria from Pfizer and Novartis; Dr Wardelmann has not reported any conflicts of interest; Dr Whelan has reported no conflicts of interest.